{"product_id":"briganix-brigatinib-2","title":"Larotreni (Larotrectinib)","description":"Larotrectinib is a treatment for solid cancers that have a neurotrophic tyrosine receptor kinase (NTRK) gene change. You might have larotrectinib for a solid cancer if: your cancer is locally advanced or advanced (metastatic) surgery to remove the cancer could cause severe health problems.\r\n\u003ch3\u003eSolid Tumors\u003c\/h3\u003e\r\nIndicated for adults and pediatric patients with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no alternative treatments or have progressed following treatment\r\n\r\n100 mg PO BID\r\n\r\nContinue until disease progression or until unacceptable toxicity\r\n\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\r\n\u003ch4\u003eDosage modifications for adverse reactions\u003c\/h4\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003e\r\n\u003ch5\u003eBody Surface Area (BSA) ≥1 m2\u003c\/h5\u003e\r\n\u003cul\u003e\r\n \t\u003cli\u003eFirst occurrence: 75 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eSecond occurrence: 50 mg BID\u003c\/li\u003e\r\n \t\u003cli\u003eThird occurrence: 100 mg qDay\u003c\/li\u003e\r\n \t\u003cli\u003eUnable to tolerate 100 mg qDay: Permanently discontinue\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Tongmeng (Lao) Pharmaceutical \u0026 Food Co., Ltd.（TLPH）","offers":[{"title":"Default Title","offer_id":44797946396715,"sku":"RL1420230901296990","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2023-12-1444.png?v=1787022074","url":"https:\/\/xomeds.com\/products\/briganix-brigatinib-2","provider":"XOMEDS","version":"1.0","type":"link"}